Top Markets
Coin of the day
Elevation Oncology, Inc. Elevation Oncology, Inc.

Elevation Oncology, Inc.

ELEV
Rank in Stocks #29359
Elevation Oncology, Inc. is a clinical-stage biopharmaceutical company... Elevation Oncology, Inc. is a clinical-stage biopharmaceutical company operating in the United States, committed to developing targeted cancer therapies for patients with specific genetic profiles. Its leading drug candidate is seribantumab, an anti-HER3 monoclonal antibody currently being evaluated in the Phase II CRESTONE trial. This study focuses on treating advanced solid tumors that harbor a neuregulin-1 fusion. The company was established in 2019 and is headquartered in New York, New York.
Share Price
$0.365
Last synced: 2025-08-01
Market Cap
$21.54M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Elevation Oncology, Inc. (ELEV)

Category

Number of shares outstanding for Elevation Oncology, Inc. (ELEV)
Number of shares outstanding as of August 2026: 0
According to Elevation Oncology, Inc. latest financial reports and stock price the company's current number of shares outstanding is 0. At the end of August 2026 the company had 0 shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Elevation Oncology, Inc. (ELEV) from 2026 to 2026
Shares Outstanding at the end of each year
Year Shares Outstanding Change
Not enough data for the provided dates.
Shares Outstanding for similar companies or competitors
Company Shares Outstanding Difference Country
253.90M -
US
62.19M -
NL
396.00M -
US
483.58M -
AU
- -
CH